TG Therapeutics, Inc.
NASDAQ:TGTX
25.71 (USD) • At close October 29, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | TG Therapeutics, Inc. |
Symbool | TGTX |
Munteenheid | USD |
Prijs | 25.71 |
Beurswaarde | 3,980,499,330 |
Dividendpercentage | 0% |
52-weken bereik | 7.17 - 26.41 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael S. Weiss Esq. |
Website | https://www.tgtherapeutics.com |
An error occurred while fetching data.
Over TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)